| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Option Care Health, Inc. Common Stock
$23.85
+0.21 (+0.89%)
Market Cap
3.57 B
EPS
1.38
P/E Ratio
17.33 $
Value Trade
54.63 M
-0.79 %
Week
0.63 %
1 Month
16.17 %
3 Month
-22.36 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
1.29 M
52 Week Range
18.01 - 36.80
% held by Insiders
1.76 %
% held by Institutions
106.6 %
Enterprise Value
4.56 B
Total Shares
149.83 M
Short %
8.18 %
Float Shares
147.28 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OPCH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OPCH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-01-15 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-OPCH
Sep 2, 2026▲ +0.9%today
Option Care Health to Participate in Upcoming Investor Conferences
Option Care Health, the largest independent provider of home infusion services, announced its participation in two upcoming investor conferences. CEO John Rademacher and CFO Meenal Sethna will represent the company at the Morgan Stanley Global Healthcare Conference and the Deutsche Bank Healthcare Summit in New York City. This engagement highlights the company's commitment to investor relations and market presence.
Read more →-OPCH
Jul 29, 2026▲ +6.5%on this news
Option Care Health Announces Financial Results For The Second Quarter Ended June 30, 2026
Option Care Health announced its financial results for Q2 2026, reporting a net revenue of $1,442 million, up 1.9% year-over-year. The company also saw a GAAP net income increase of 6.7%, reaching $53.9 million. Looking ahead, Option Care Health expects continued growth in revenue and adjusted EBITDA for the full year and Q3 2026, supported by its strategic initiatives.
Read more →-OPCH
Jul 9, 2026Option Care Health to Announce Second Quarter 2026 Financial Results and Host Conference Call
Option Care Health Inc. will announce its second quarter financial results for 2026 on July 29, 2026, before the market opens. A conference call is scheduled for the same day at 8:30 a.m. E.T. to discuss the results. Participants can pre-register for the call or access it via a live audio webcast.
Read more →-OPCH
May 12, 2026Extraordinary Care That Changes Lives 2026 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED Option Care Health, Inc. Bank of America Global Healthcare Conference
Option Care Health, Inc. presented a range of financial information, including non-GAAP measures, during the Bank of America Global Healthcare Conference. Management emphasized the importance of these adjusted metrics for providing insights into the company's operational performance and in facilitating comparisons to historical results. However, they also cautioned that actual results might differ from forward-looking statements due to inherent risks and uncertainties, including regulatory changes and market conditions. The presentation included a disclaimer regarding the potential for changes that impact the company's future performance.
Read more →-OPCH
May 4, 2026▲ +5.5%on this news
Option Care Health to Participate in the Bank of America Health Care Conference
Option Care Health, the largest independent provider of home infusion services, will participate in the Bank of America Health Care Conference on May 12, 2026. The event will feature a fireside chat at 10:40am PT/1:40pm ET, providing an opportunity for the company to engage with investors. The webcast will be accessible online.
Read more →-OPCH
Apr 30, 2026▼ -24.3%on this newsshared move
Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2026
Option Care Health reported its financial results for Q1 2026, showing a mixed performance. While net revenue increased by 1.3%, GAAP net income declined by 3.0%. The company has updated its full-year guidance, expecting net revenue between $5.675 billion and $5.775 billion. A conference call is scheduled to discuss these results further.
Read more →-OPCH
Feb 24, 2026▼ -6.3%on this news
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2025 BANNOCKBURN, IL.
Option Care Health, Inc. reported its financial results for the fourth quarter and the full year of 2025, revealing a net revenue increase of 13.0% for the full year. However, despite the revenue growth, net income saw a decrease of 2.0% year-over-year. The company also highlighted significant stock repurchases amounting to $402 million, indicating strong cash flow and investor confidence. Looking ahead, Option Care Health anticipates further growth, projecting 2026 revenues between $5.8 billion and $6.0 billion.
Read more →-OPCH
Jan 22, 2026Option Care Health to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call
Option Care Health Inc. will announce its fourth quarter and full year 2025 financial results on February 24, 2026, before market opening. The management team will host a conference call at 8:30 a.m. E.T. to discuss the results. Participants can pre-register for the call and access a live audio webcast.
Read more →-OPCH
Jan 12, 2026OPTION CARE HEALTH ANNOUNCES PRELIMINARY FOURTH QUARTER & FULL YEAR 2025 FINANCIAL RESULTS AND PRELIMINARY FINANCIAL GUIDANCE FOR FULL YEAR 2026 BANNOCKBURN, IL.
Option Care Health has announced its preliminary fourth quarter and full year 2025 financial results, along with preliminary guidance for 2026. The company expects to provide more detailed guidance during its upcoming earnings call. Additionally, the company's board has approved an increase in the share repurchase program from $500 million to $1 billion, emphasizing its commitment to returning value to shareholders. Investor engagement will continue with a presentation at the J.P. Morgan Healthcare Conference in January.
Read more →-OPCH
Oct 30, 2025▼ -8.6%on this news
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 BANNOCKBURN, IL.
Option Care Health, Inc. announced its financial results for the third quarter ended September 30, 2025, reporting a net revenue of $1.435 billion, reflecting a 12.2% increase year-over-year. Despite the revenue growth, net income experienced a decrease of 3.8%. The company also provided an updated financial guidance for the full year, expecting net revenue between $5.60 billion and $5.65 billion. CEO John C. Rademacher highlighted the company's strong performance amid a dynamic regulatory environment.
Read more →-OPCH
Aug 20, 2025Option Care Health Announces Chief Financial Officer Transition Mike Shapiro to Step Down After 10 Years With the Company; Meenal Sethna Named EVP and CFO Effective
Option Care Health has announced a leadership transition with Meenal Sethna taking over as Chief Financial Officer effective October 1, 2025, succeeding Mike Shapiro after a decade-long tenure. Shapiro will remain with the company as a Strategic Advisor until at least the first quarter of 2026. Sethna, who has extensive experience in finance and accounting across multiple industries, expressed her enthusiasm for joining the company and contributing to its growth and value creation. The transition is seen as a strategic move to sustain the company's positive momentum in the infusion services sector.
Read more →-OPCH
Jul 30, 2025OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 BANNOCKBURN, IL.
Option Care Health reported a strong financial performance for the second quarter of 2025, with net revenue increasing by 15.4% year-over-year, totaling $1,416.1 million. Despite a slight decrease in net income from $53.0 million in the previous year to $50.5 million, adjusted diluted earnings per share rose by 10.8%. The company has also updated its full-year guidance, expecting net revenue between $5.50 billion and $5.65 billion. CEO John C. Rademacher highlighted the team's resilience in a dynamic marketplace.
Read more →-OPCH
Apr 29, 2025▼ -6.9%on this news
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 BANNOCKBURN, IL.
Option Care Health, Inc. reported its financial results for the first quarter ended March 31, 2025, highlighting a significant increase in net revenue to $1.333 billion, up 16.3% from the previous year. The gross profit also rose to $263.1 million, although it represented a slight decline in percentage of revenue compared to last year. Notably, adjusted net income improved to $67.1 million and the company successfully repurchased approximately $100 million in stock during the quarter. The company is optimistic about 2025, adjusting their financial guidance to project a net revenue between $5.4 billion and $5.6 billion.
Read more →-OPCH
Feb 26, 2025OPTION CARE HEALTH REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2024 BANNOCKBURN, IL.
Option Care Health reported robust financial results for the fourth quarter and full year 2024, with a significant increase in net revenue and adjusted diluted earnings per share. Q4 2024 net revenue rose to $1.346 billion, reflecting a year-over-year increase of 19.7%. However, full year net income decreased to $211.8 million, down from $267.1 million in 2023. The company also anticipates positive growth for 2025, projecting net revenues between $5.3 billion and $5.5 billion.
Read more →-OPCH
Jan 13, 2025▲ +15.5%on this news
OPTION CARE HEALTH ANNOUNCES PRELIMINARY FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2024 AND PRELIMINARY FINANCIAL EXPECTATIONS FOR FULL YEAR 2025 BANNOCKBURN, IL.
Option Care Health, Inc. announced preliminary financial results for the fourth quarter and full year 2024, including guidance for 2025. The company anticipates a negative gross profit impact due to pricing adjustments related to Stelara. Further details will be provided in a financial call scheduled for February 2025. Additionally, Option Care concluded a $90 million share repurchase program and has initiated a new $500 million program.
Read more →-OPCH
Oct 30, 2024▼ -22.8%on this news
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2024 BANNOCKBURN, IL.
Option Care Health, the largest independent provider of home and alternate site infusion services, announced its financial results for Q3 2024, reporting a net revenue of $1,278.5 million, up 17.0% from the previous year. Despite the revenue increase, net income and adjusted net income experienced declines of 4.3% and 3.2%, respectively. The company is facing supply chain disruptions due to Hurricane Helene, which will adversely affect its financial guidance for the fourth quarter. Option Care Health maintains a strong cash flow from operations and has repurchased significant amounts of its stock.
Read more →-OPCH
Jul 31, 2024▼ -5.3%on this news
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2024 BANNOCKBURN, IL.
Option Care Health reported its financial results for the second quarter ended June 30, 2024. The company achieved a net revenue increase of 14.8% year-over-year, totaling $1,227.2 million, but faced a significant decline in net income, which fell by 53.6% to $53 million. Additionally, while cash flow from operations improved, the gross profit margin decreased as well. The company also provided financial guidance for the full year 2024, maintaining expectations for revenue and adjusted EBITDA.
Read more →-OPCH
Apr 23, 2024OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2024 BANNOCKBURN, IL.
Option Care Health announced its financial results for the first quarter ended March 31, 2024, reporting a net revenue of $1,146.1 million, representing a 12.8% increase from the same quarter last year. The company's net income reached $44.8 million, or $0.26 per share, reflecting a 14.2% increase. However, cash flow from operations fell to $(68.8) million compared to $89.8 million in the previous year, primarily due to a cybersecurity incident. Despite some challenges, the company maintained a positive outlook and reaffirmed its full-year financial guidance.
Read more →-OPCH
Feb 22, 2024OPTION CARE HEALTH REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2023 BANNOCKBURN, IL.
Option Care Health, Inc. reported a strong financial performance for Q4 and the full year 2023, showcasing significant revenue and profit growth. The company generated net revenue of $1,124.4 million for the fourth quarter, an increase from the previous year's quarter. Full year 2023 results also reflected a rise in net income and adjusted EBITDA. Looking forward, Option Care is predicting continued growth with guidance for 2024 net revenue between $4.6 billion and $4.8 billion.
Read more →-OPCH
Oct 25, 2023▼ -15.5%on this news
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2023 BANNOCKBURN, IL.
Option Care Health announced its financial results for Q3 2023, reporting net revenue of $1,093.0 million, which is a 7.1% increase from the same period last year. The gross profit also improved significantly, rising by 16.6% to $254.3 million. Furthermore, net income saw a notable increase of 45.0%, reaching $56.3 million. However, cash flow from operations has decreased compared to the prior year's quarter.
Read more →-OPCH
Jul 27, 2023OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2023 BANNOCKBURN, IL.
Option Care Health reported strong financial results for Q2 2023, with net revenue increasing to $1,069.1 million, up 9.0% from the previous year. The company experienced a substantial gain in net income, reaching $114.4 million, a 237.2% increase compared to Q2 2022. Notably, adjusted EBITDA also improved by 29.2%, demonstrating effective management of operating costs. However, the company has recently terminated a proposed merger with Amedisys, receiving a $106 million payment in the process. The outlook for the full year remains optimistic, projecting net revenues of $4.2 to $4.3 billion.
Read more →-OPCH
Jun 26, 2023▲ +5.2%on this news
Option Care Health Confirms Termination of Merger Agreement with Amedisys Highlights Strength of Platform and Track Record of Execution and Value Creation
Option Care Health has announced the termination of its merger agreement with Amedisys, which includes a $106 million termination fee that the company will integrate into its capital allocation strategy. The CEO emphasized the company’s resilience and ongoing commitment to creating shareholder value despite this setback. Option Care Health remains confident in its growth trajectory, supported by strong industry trends and its proven operational capabilities. This decision will allow the company to focus on enhancing its services in home and alternate site infusion.
Read more →-OPCH
May 3, 2023Option Care Health and Amedisys to Combine Creating a Leading, Independent Platform for Home and Alternate Site Care All-Stock Transaction Combines Highly Complementary Businesses Unlocking Significant Benefits for Patie
Option Care Health and Amedisys have announced a merger agreement to combine their businesses in an all-stock transaction valued at approximately $3.6 billion. This merger aims to create a market leader in home and alternate site care, enhancing access to quality healthcare services across the U.S. The combined company is projected to generate significant operational synergies, including anticipated annual run-rate revenue and cost synergies of about $75 million by year three. The transaction, which has been approved by the Boards of Directors of both companies, is expected to close in the second half of 2023, pending stockholder approvals and regulatory clearances.
Read more →-OPCH
May 3, 2023OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2023 BANNOCKBURN, IL.
Option Care Health announced strong financial results for Q1 2023, with net revenue reaching $1,015.8 million, a 10.9% increase from Q1 2022. The company also reported a net income of $39.2 million, marking a 29.5% rise from the prior year. Furthermore, Option Care launched Naven Health and received recognition from Gallup for workplace excellence. The company issued updated guidance for 2023, anticipating significant revenue growth amid strategic changes and pending merger with Amedisys.
Read more →-OPCH
Feb 23, 2023▲ +10.5%on this news
OPTION CARE HEALTH REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2022
Option Care Health reported optimistic financial results for Q4 and the full year 2022, with net revenue and adjusted EBITDA showing significant increases compared to the previous year. The company achieved a net revenue of $1,027.2 million for Q4 and $3,944.7 million for the full year, reflecting robust growth. Additionally, a share repurchase program of up to $250 million was authorized, which underscores the company's positive outlook for 2023. Overall, the financial performance positions Option Care Health well for future opportunities.
Read more →-OPCH
Oct 27, 2022▼ -12.1%on this news
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2022 BANNOCKBURN, IL.
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2022 BANNOCKBURN, IL., October 27, 2022 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq OPCH), the nation's largest independent provider of home and alternate site
Read more →-OPCH
Jul 27, 2022OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2022 BANNOCKBURN, IL.
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2022 BANNOCKBURN, IL., July 27, 2022 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq OPCH), the nation's largest independent provider of home and alternate site infusi
Read more →-OPCH
Apr 28, 2022▲ +12.5%on this news
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2022 BANNOCKBURN, IL.
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2022 BANNOCKBURN, IL., April 28, 2022 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq OPCH), the nation's largest independent provider of home and alternate site infus
Read more →-OPCH
Feb 23, 2022▲ +5.3%on this news
OPTION CARE HEALTH REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2021
OPTION CARE HEALTH REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2021 AND ANNOUNCES TWO ADDITIONAL ACQUISITIONS BANNOCKBURN, IL., February 23, 2022 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq OPCH), the nation's largest independent pro
Read more →-OPCH
Nov 4, 2021OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2021 BANNOCKBURN, IL.
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2021 BANNOCKBURN, IL., November 4, 2021 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq OPCH), the nation's largest independent provider of home and alternate site
Read more →-OPCH
Oct 22, 2021OPTION CARE HEALTH ANNOUNCES PRICING OF OFFERING OF $500 MILLION 4.375%
OPTION CARE HEALTH ANNOUNCES PRICING OF OFFERING OF $500 MILLION 4.375% SENIOR NOTES AND AMENDMENT AND EXTENSION OF FIRST LIEN TERM LOAN BANNOCKBURN, Ill., October 22, 2021 -- Option Care Health, Inc. (NASDAQ: OPCH) ("Option Care Health" or the "Company") announced today that
Read more →-OPCH
Oct 20, 2021▲ +6.4%on this newsshared move
OPTION CARE HEALTH ANNOUNCES OFFERING OF $500
OPTION CARE HEALTH ANNOUNCES OFFERING OF $500 MILLION OF SENIOR NOTES AND AMENDMENT AND EXTENSION OF FIRST LIEN TERM LOAN BANNOCKBURN, Ill., October 20, 2021 -- Option Care Health, Inc. (NASDAQ: OPCH) ("Option Care Health" or the "Company") announced today that it intends to o
Read more →-OPCH
Oct 20, 2021▲ +6.4%on this newsshared move
OPTION CARE HEALTH ANNOUNCES PRELIMINARY FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2021
OPTION CARE HEALTH ANNOUNCES PRELIMINARY FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2021 AND SCHEDULES THIRD QUARTER EARNINGS CALL October 20, 2021 -- Option Care Health, Inc. (NASDAQ: OPCH) ("Option Care Health" or the "Company"), the nation's largest indepen
Read more →-OPCH
Aug 3, 2021OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2021 BANNOCKBURN, IL.
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2021 BANNOCKBURN, IL., August 3, 2021 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq OPCH), the nation's largest independent provider of home and alternate site infus
Read more →-OPCH
May 6, 2021OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2021 BANNOCKBURN, IL.
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2021 BANNOCKBURN, IL., May 6, 2021 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq OPCH), the nation's largest independent provider of home and alternate site infusion
Read more →-OPCH
Mar 11, 2021OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2020 AND PROVIDES GUIDANCE FOR FULL YEAR 2021 BANNOCKBURN, IL.
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2020 AND PROVIDES GUIDANCE FOR FULL YEAR 2021 BANNOCKBURN, IL., March 11, 2021 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq OPCH), the nation's largest independent provi
Read more →-OPCH
Jan 21, 2021OPTION CARE HEALTH ANNOUNCES ISSUANCE OF $250
OPTION CARE HEALTH ANNOUNCES ISSUANCE OF $250 MILLION IN ADDITIONAL FIRST LIEN TERM LOAN AND CONCURRENT EXTINGUISHMENT OF ALL OUTSTANDING SECOND LIEN NOTES BANNOCKBURN, Ill., January 21, 2021 -- Option Care Health Inc. (NASDAQ: OPCH)("Option Care Health" or the Company"), the
Read more →-OPCH
Nov 3, 2020OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2020 BANNOCKBURN, IL.
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2020 BANNOCKBURN, IL., November 3, 2020 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq OPCH), the nation's largest independent provider of home and alternate site
Read more →-OPCH
Jun 26, 2020UNAUDITED PRO FORMA COMBINED FINANCIAL STATEMENTS On
UNAUDITED PRO FORMA COMBINED FINANCIAL HC Group Holdings I, LLC ("HC I") and HC Group Holdings II, Inc. ("HC II") entered into a definitive agreement (the "Merger Agreement") to merge with and into a wholly-owned subsidiary of BioScrip, Inc. ("BioScrip"), a national provider o
Read more →-OPCH
May 7, 2020OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER AND PROVIDES AN UPDATE ON THE IMPACT OF COVID-19
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER AND PROVIDES AN UPDATE ON THE IMPACT OF COVID-19 PANDEMIC BANNOCKBURN, IL., May 7, 2020 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq: OPCH), the nation's largest independent provid
Read more →-OPCH
Mar 5, 2020OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2019 AND ANNOUNCES GUIDANCE FOR FULL YEAR 2020 BANNOCKBURN, IL.
OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL YEAR 2019 AND ANNOUNCES GUIDANCE FOR FULL YEAR 2020 BANNOCKBURN, IL., March 5, 2020 - Option Care Health, Inc. (the "Company" or "Option Care Health") (Nasdaq: OPCH), the nation's largest independent prov
Read more →-OPCH
Feb 3, 2020Option Care Health completes
Care Health completes REVERSE STOCK SPLIT AND TICKER SYMBOL CHANGE BANNOCKBURN, IL., February 3, 2020 - Option Care Health, Inc. (the "Company" or "Option Care Health") (NASDAQ: OPCH), the nation's largest independent provider of home and alternate site infusion services, anno
Read more →-OPCH
Dec 27, 2019GRANTED IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE ERIK SCHMIDT, on behalf of himself and all other similarly situated stockholders of BIOSCRIP, INC., Plaintiff, v. C.A. No. 2019-0430-SG R. CARTER PATE, DANIEL E.
GRANTED IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE ERIK SCHMIDT, on behalf of himself and all other similarly situated stockholders of BIOSCRIP, INC., Plaintiff, v. C.A. No. 2019-0430-SG R. CARTER PATE, DANIEL E. GREENLEAF, DAVID GOLDING, MICHAEL GOLDSTEIN, CHRISTOPH
Read more →-OPCH
Aug 13, 2019Option Care Health Receives Anticipated Nasdaq Notice Intends to Request Appeals Hearing and to Take Other Action to Maintain Listing
Option Care Health Receives Anticipated Intends to Request Appeals Hearing and to Take Other Action to Maintain Listing BANNOCKBURN, Ill., August 13, 2019 - Option Care Health, Inc. (Nasdaq: BIOS) announced today that on August 7, 2019, it received a letter from the Nasdaq St
Read more →-OPCH
Aug 7, 2019HC Group Holdings II, Inc. Quarterly Report for the Quarterly Period Ended
HC Group Holdings II, Inc. Quarterly Report for the Quarterly Period Ended June 30, 2019 HC Group Holdings II, Inc. Page Condensed Consolidated Balance Sheets as of June 30, 2019 (unaudited) and December 31, 2018 (audited) 1 Unaudited Condensed Consolidated Statements of Comp
Read more →-OPCH
Aug 2, 2019BioScrip Announces Shareholder Approval of Merger with Option Care DENVER, CO
BioScrip Announces Shareholder Approval of Merger with Option Care DENVER, CO, August 2, 2019 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced that its stoc
Read more →-OPCH
Jul 30, 2019BioScrip Reports Second Quarter 2019 Financial Results DENVER, CO
BioScrip Reports Second Quarter 2019 DENVER, CO, July 30, 2019 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its second quarter 2019 financial results. S
Read more →-OPCH
Jun 13, 2019Key Members of BioScrip's Leadership Team to Continue in Executive Roles with Combined Company Following Close of Option Care Merger DENVER
Key Members of BioScrip's Leadership Team to Continue in Executive Roles with Combined Company Following Close of Option Care Merger DENVER, June 13, 2019 -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip"), the largest independent national provider of infusion and home care managem
Read more →-OPCH
May 2, 2019BioScrip Reports First Quarter 2019 Financial Results DENVER, CO
BioScrip Reports First Quarter 2019 Financial DENVER, CO, May 2, 2019 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its first quarter 2019 financial resul
Read more →-OPCH
Apr 23, 2019BioScrip, Inc. Provides Merger Update DENVER, CO
Inc. Provides Merger Update April 23, 2019 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today provided an update on its proposed merger with Option Care Enterprises, Inc
Read more →-OPCH
Mar 15, 2019Home and Alternate Site Infusion Therapy Providers BioScrip and Option Care to Merge Creates a Leading Independent Provider of Home and Alternate Site Infusion Services with Deep Clinical Expertise and Broad Therapy Port
Home and Alternate Site Infusion Therapy Providers BioScrip and Option Care to Merge Creates a Leading Independent Provider of Home and Alternate Site Infusion Services with Deep Clinical Expertise and Broad Therapy Enhanced Scale and Improved Financial Profile Expected to
Read more →-OPCH
Mar 15, 2019BioScrip Reports Fourth Quarter and Full Year 2018 Financial Results DENVER, CO
BioScrip Reports Fourth Quarter and Full Year 2018 Financial Results DENVER, CO, March 15, 2019 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its fourth
Read more →-OPCH
Nov 6, 2018BioScrip Reports Third Quarter 2018 Financial Results DENVER, CO
BioScrip Reports Third Quarter 2018 Financial DENVER, CO, November 6, 2018 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its third quarter 2018 financial
Read more →-OPCH
Nov 1, 2018BioScrip Comments on Implementation of Medicare Home Infusion Transition Benefit -- Reaffirming Guidance for 2019 Adjusted EBITDA of at least $75 million -- DENVER
BioScrip Comments on Implementation of Medicare Home Infusion Transition Benefit -- Reaffirming Guidance for 2019 Adjusted EBITDA of at least $75 million -- DENVER, November 1, 2018 -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent natio
Read more →-OPCH
Oct 22, 2018BioScrip Appoints John McMahon as Chief Accounting Officer DENVER
BioScrip Appoints John McMahon as Chief DENVER, October 22, 2018 -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced the appointment of John McMahon as Vice Pre
Read more →-OPCH
Aug 7, 2018BioScrip Reports Second Quarter 2018 Financial Results DENVER, CO
BioScrip Reports Second Quarter 2018 DENVER, CO, August 7, 2018 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its second quarter 2018 financial results.
Read more →-OPCH
May 10, 2018BioScrip Reports First Quarter 2018 Financial Results DENVER, CO
BioScrip Reports First Quarter 2018 Financial Results DENVER, CO, May 10, 2018 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its first quarter 2018 finan
Read more →-OPCH
Mar 8, 2018BioScrip Reports Fourth Quarter and Full Year 2017 Financial Results DENVER, CO
BioScrip Reports Fourth Quarter and Full Year 2017 Financial Results DENVER, CO, March 8, 2018 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its prelimin
Read more →-OPCH
Nov 28, 2017BioScrip Announces Additions to Senior Leadership Team Appoints Harriet Booker as Senior Vice President, Chief Operating Officer and Danny R. Claycomb as Senior Vice President, Revenue Cycle Management DENVER
BioScrip Announces Additions to Senior Appoints Harriet Booker as Senior Vice President, Chief Operating Officer and Danny R. Claycomb as Senior Vice President, Revenue Cycle Management DENVER, Nov. 28, 2017 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the
Read more →-OPCH
Nov 2, 2017BioScrip Reports Third Quarter 2017 Financial Results - Net revenue of $198.7 million, including core product mix of 75.0%, compared to 65.8% in the prior year - Net revenue and adjusted EBITDA reduced $10.0 million and
BioScrip Reports Third Quarter 2017 Financial DENVER, CO, November 2, 2017 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its third quarter 2017 financial
Read more →-OPCH
Aug 9, 2017BioScrip Reports Second Quarter 2017 Financial Results - Net revenue of $218.1 million, including core product mix of 73.1% compared to 60.3% in the prior year - Net loss from continuing operations of $28.7 million, comp
BioScrip Reports Second Quarter 2017 DENVER, CO, August 8, 2017 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and home care management solutions, today announced its second quarter 2017 financial results. F
Read more →-OPCH
Jun 29, 2017BioScrip Announces New Senior Credit Facility Agreement Will Immediately Improve Capital Structure, Provide Operational Flexibility, and Result in Excess of $50 million in Liquidity DENVER
BioScrip Announces New Senior Credit Agreement Will Immediately Improve Capital Structure, Provide Operational Flexibility, and Result in Excess of $50 million in Liquidity DENVER, June 29, 2017 -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest indep
Read more →-OPCH
May 4, 2017BioScrip Reports First Quarter 2017 Financial
BioScrip Reports First Quarter 2017 Financial Q1 Consolidated Revenue of $217.8 Million, loss from continuing operations net of income taxes of $19.0 million and Adjusted EBITDA of $5.2 Million DENVER, CO, May 4, 2017 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Compan
Read more →-OPCH
Apr 20, 2017BioScrip Announces CFO Transition Appoints Stephen M. Deitsch as Senior Vice President, Chief Financial Officer and Treasurer DENVER
BioScrip Announces CFO Transition Appoints Stephen M. Deitsch as Senior Vice President, Chief Financial Officer and Treasurer DENVER, April 20, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), a leading national provider of infusion and home care management
Read more →-OPCH
Mar 27, 2017BioScrip Announces Meeting with Investors Company Expects Improved Profitability Following Termination of Agreement with UnitedHealthcare DENVER
Announces Meeting with Investors Expects Improved Profitability Following Termination of Agreement with UnitedHealthcare DENVER, March 27, 2017 -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), a leading national provider of infusion and home care management solu
Read more →-OPCH
Mar 3, 2017BioScrip Reports Fourth Quarter and Full-Year 2016 Financial Results Q4 Consolidated Revenue of $240.1 Million, loss from continuing operations net of income taxes of ($5.2) million and Adjusted EBITDA of $9.5 Million DE
BioScrip Reports Fourth Quarter and Full-Year 2016 Financial Results Q4 Consolidated Revenue of $240.1 Million, loss from continuing operations net of income taxes of ($5.2) million and Adjusted EBITDA of $9.5 Million DENVER, CO, March 3, 2017 - BioScrip, Inc. (NASDAQ: BIOS)
Read more →-OPCH
Mar 2, 2017BioScrip Raises Approximately $5 million in Private Placement of Common Stock DENVER
BioScrip Raises Approximately $5 million in Private Placement of Common Stock DENVER, March 2, 2017 - BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), a leading national provider of infusion and home care management solutions, today announced that it entered into a
Read more →-OPCH
Jan 9, 2017BioScrip Announces Amendment to Credit
BioScrip Announces Amendment to Credit Agreement and New Senior Loan Facility DENVER, January 6, 2017 - BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), a leading national provider of infusion and home care management solutions, today announced that it has entered
Read more →-OPCH
Dec 14, 2016BioScrip Inc. All rights reserved. Bank Meeting Proposed Amendment to Credit Agreement 2012 BioScrip Inc. All rights reserved. 2 Disclaimer The information contained herein has not been independently verified . The Compa
None of the Company or its respective affiliates or representatives undertakes any obligation to update any of the information contained herein . This document contains an estimate of projected adjusted EBITDA. Projected adjusted EBITDA as used in this presentation is consistent
Read more →-OPCH
Nov 7, 2016Jeffrey M. Kreger Chief Financial Officer (720) 697-5200 Jeffrey.kreger@bioscrip.com BioScrip Reports Third Quarter 2016 Financial Results Q3 Consolidated Revenue of $224.5 Million, Loss from continuing operatio
Chief Financial Officer Jeffrey.kreger@bioscrip.com BioScrip Reports Third Quarter 2016 Financial Q3 Consolidated Revenue of $224.5 Million, Loss from continuing operations, net of income taxes of $(11.1) Million and Adjusted EBITDA of $3.5 Million DENVER, CO, November 7, 2
Read more →-OPCH
Sep 9, 2016BioScrip Completes Acquisition of Home Solutions DENVER
BioScrip Completes Acquisition of Home DENVER, September 9, 2016 -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), a leading national provider of infusion and home care management solutions, today announced that it has completed the acquisition of HS Infusion Hold
Read more →-OPCH
Sep 2, 2016BioScrip and Home Solutions Enter Into Amended Asset Purchase Agreement to Expedite Closing DENVER and HAMMONTON, N.J.
BioScrip and Home Solutions Enter Into Amended Asset Purchase Agreement to Expedite Closing DENVER and HAMMONTON, N.J., September 2, 2016 -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), a leading national provider of infusion and home care management solutions
Read more →-OPCH
Aug 12, 2016Jeffrey M. Kreger Chief Financial Officer (720) 697-5200 Jeffrey.kreger@bioscrip.com BioScrip Enters into a Tax Asset Protection Plan to Protect its Valuable Tax Assets DENVER, CO.
Chief Financial Officer Jeffrey.kreger@bioscrip.com BioScrip Enters into a Tax Asset Protection Plan to Protect its Valuable Tax Assets DENVER, CO., - August 12, 2016 -BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company") today announced that its Board of Directors has
Read more →-OPCH
Aug 8, 2016Jeffrey M. Kreger Chief Financial Officer (720) 697-5200 Jeffrey.kreger@bioscrip.com BioScrip Reports Second Quarter 2016 Financial Results Q2 Consolidated Revenue of $232.5 Million, Loss from continuing operati
Chief Financial Officer Jeffrey.kreger@bioscrip.com BioScrip Reports Second Quarter 2016 Q2 Consolidated Revenue of $232.5 Million, Loss from continuing operations, net of income taxes of $(8.3) Million and Adjusted EBITDA of $10.4 Million Full Year 2016 Guidance Updated to
Read more →-OPCH
Jun 22, 2016BIOSCRIP
COMPLETES PUBLIC OFFERING OF COMMON STOCK June 22, 2016 - BioScrip, Inc. (NASDAQ: BIOS) (the "Company" or "BioScrip") announced today that it has completed its previously announced underwritten public offering (the "Offering") of 45,200,000 shares of its common stock, includin
Read more →-OPCH
Jun 16, 2016Jeffrey M. Kreger BioScrip Chief Financial Officer (720) 697-5200 jeffrey.kreger@bioscrip.com BIOSCRIP AND HOME SOLUTIONS ENTER INTO AMENDED AGREEMENT Amendment Further Enhances Value for Shareholders Accretive
BioScrip Chief Financial Officer jeffrey.kreger@bioscrip.com BIOSCRIP AND HOME SOLUTIONS ENTER INTO Amendment Further Enhances Value for Accretive Transaction Provides Substantial Operating Synergies and Deleveraging Opportunity DENVER and HAMMONTON, N.J., June 16, 2016 --
Read more →-OPCH
Jun 13, 2016Jeffrey M. Kreger BioScrip Chief Financial Officer (720) 697-5200 jeffrey.kreger@bioscrip.com BIOSCRIP ANNOUNCES TRANSFORMATIVE ACQUISITION OF HOME SOLUTIONS THAT WILL ENHANCE FOCUS AS HOME INFUSION LEADER Combi
BioScrip Chief Financial Officer jeffrey.kreger@bioscrip.com BIOSCRIP ANNOUNCES TRANSFORMATIVE ACQUISITION OF HOME SOLUTIONS THAT WILL ENHANCE FOCUS AS HOME INFUSION LEADER Combination with Home Solutions Adds Experienced and Proven Leadership Team Accretive Transaction Pro
Read more →-OPCH
Jun 1, 2016BIOSCRIP, INC. 1600 Broadway, Suite 950 Denver, Colorado 80202 (720) 697-5200 NOTICE OF ACTION WITHOUT A MEETING OF THE HOLDERS OF BIOSCRIP, INC. SERIES A
1600 Broadway, Suite 950 Denver, Colorado 80202 NOTICE OF ACTION WITHOUT A MEETING OF THE HOLDERS OF BIOSCRIP, INC. SERIES A CONVERTIBLE PREFERRED STOCK To holders of BioScrip, Inc. Series A Convertible Preferred Notice is hereby given to holders of Series A Convertible Pr
Read more →-OPCH
May 5, 2016Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com BioScrip Reports First Quarter 2016 Financial Results DENVER, CO
In-Site Communications, Inc. E: lwilson@insitecony.com BioScrip Reports First Quarter 2016 Financial DENVER, CO, May 5, 2016 - BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company") today announced financial results for the first quarter 2016. For the first quarter, the
Read more →-OPCH
Mar 2, 2016Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com BioScrip Reports Fourth Quarter 2015 Financial Results Q4 Consolidated Adjusted EBITDA of $9.0 Million Reaffirms 2016 Adjusted E
In-Site Communications, Inc. E: lwilson@insitecony.com BioScrip Reports Fourth Quarter 2015 Q4 Consolidated Adjusted EBITDA of $9.0 Reaffirms 2016 Adjusted EBITDA Guidance of Between $50 Million - $60 Million DENVER, CO, March 2, 2016 - BioScrip, Inc. (NASDAQ: BIOS) ("BioS
Read more →-OPCH
Jan 19, 2016Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com BIOSCRIP PROVIDES BUSINESS UPDATE ON IMPLEMENTATION OF FINANCIAL IMPROVEMENT PLAN AND PROGRESS TO ENHANCE SHAREHOL
In-Site Communications, Inc. E: lwilson@insitecony.com BIOSCRIP PROVIDES BUSINESS UPDATE ON IMPLEMENTATION OF FINANCIAL IMPROVEMENT PLAN AND PROGRESS TO ENHANCE SHAREHOLDER VALUE Review of Strategic Alternatives Continues Patient Census Growth Continues, Cost Savings Initi
Read more →-OPCH
Nov 4, 2015Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com FOR IMMEDIATE RELEASE BioScrip Reports Third Quarter 2015 Financial Results Consolidated Adjusted EBITDA of $6.2 Million Results
In-Site Communications, Inc. E: lwilson@insitecony.com BioScrip Reports Third Quarter 2015 Financial Consolidated Adjusted EBITDA of $6.2 Results Demonstrate Progress Against Financial Improvement Plan Reaffirms 2016 Adjusted EBITDA Guidance of Between $50 Million - $60 Mi
Read more →-OPCH
Aug 27, 2015BIOSCRIP, INC. AND SUBSIDIARIES UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION PBM Business Sale On
BIOSCRIP, INC. AND SUBSIDIARIES UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL On August 27, 2015, BioScrip, Inc. (the "Company") completed its previously announced sale of the Company's PBM Services segment (the "PBM Business") pursuant to the Asset Purchase Agreement dated as o
Read more →-OPCH
Aug 10, 2015Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com FOR IMMEDIATE RELEASE BIOSCRIP ANNOUNCES STEPS TO ENHANCE SHAREHOLDER VALUE Implementing $35 Million - $40 Million
In-Site Communications, Inc. E: lwilson@insitecony.com ANNOUNCES STEPS TO ENHANCE SHAREHOLDER VALUE Implementing $35 Million - $40 Million in Total Cost Savings Over the Next 12 Months to Improve Financial Performance and Increase Takes Steps to Enhance Liquidity and Provi
Read more →-OPCH
Jul 28, 2015Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com FOR IMMEDIATE RELEASE BioScrip, Inc. Announces Expiration and Results of Rights Offering ELMSFORD, N.Y.
In-Site Communications, Inc. E: lwilson@insitecony.com BioScrip, Inc. Announces Expiration and Results of Rights Offering ELMSFORD, N.Y., July 28, 2015 -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip") today announced the expiration of the subscription period for its previously
Read more →-OPCH
Jun 19, 2015Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com FOR IMMEDIATE RELEASE BioScrip announces COMPLETION OF EXCHANGE OFFER FOR ITS 8.875% SENIOR NOTES DUE 2021 Elmsford
In-Site Communications, Inc. E: lwilson@insitecony.com announces COMPLETION OF EXCHANGE OFFER FOR ITS 8.875% SENIOR NOTES DUE 2021 Elmsford, NY - June 19, 2015 - BioScrip , Inc. (NASDAQ: BIOS) ("BioScrip"), today announced that it has completed its exchange offer (the "Exchan
Read more →-OPCH
Jun 18, 2015Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com FOR IMMEDIATE RELEASE BioScrip, Inc. Announces Record Date for Rights Offering Elmsford, NY
In-Site Communications, Inc. E: lwilson@insitecony.com Inc. Announces Record Date for Rights Offering Elmsford, NY - June 18, 2015 - BioScrip, Inc. (NASDAQ: BIOS) (the "Company") today announced that its Board of Directors set the record date for the previously disclosed upc
Read more →-OPCH
Jun 10, 2015Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com FOR IMMEDIATE RELEASE BioScrip announces EXTENSION OF EXPIRATION DATE OF EXCHANGE OFFER FOR ITS 8.875% SENIOR NOTES
In-Site Communications, Inc. E: lwilson@insitecony.com announces EXTENSION OF EXPIRATION DATE OF EXCHANGE OFFER FOR ITS 8.875% SENIOR NOTES DUE 2021 Elmsford, NY - June 10, 2015 - BioScrip , Inc. (NASDAQ: BIOS) ("BioScrip"), today announced the extension of the expiration dat
Read more →-OPCH
May 7, 2015Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com FOR IMMEDIATE RELEASE BIOSCRIP REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS Elmsford, NY
In-Site Communications, Inc. E: lwilson@insitecony.com BIOSCRIP REPORTS FIRST QUARTER 2015 FINANCIAL Elmsford, NY - May 7, 2015 - BioScrip, Inc. (NASDAQ: BIOS) (the "Company") today announced 2015 first quarter financial results. First quarter revenue from continuing operatio
Read more →-OPCH
Apr 27, 2015Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com BioScrip Appoints Veteran Finance Executive Jeffrey M. Kreger as Chief Financial Officer ELMSFORD, N.Y.
In-Site Communications, Inc. E: lwilson@insitecony.com BioScrip Appoints Veteran Finance Executive as Chief Financial Officer ELMSFORD, N.Y., April 27, 2015 /PRNewswire/ -- BioScrip, Inc. (NASDAQ: BIOS) ("BioScrip"), a leading national provider of infusion and home care mana
Read more →-OPCH
Mar 9, 2015Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com BioScrip Raises $62.5 million in Private Placement of Convertible Preferred Stock and Announces Plan for $20 milli
In-Site Communications, Inc. E: lwilson@insitecony.com BioScrip Raises $62.5 million in Private Placement of Convertible Preferred Stock and Announces Plan for $20 million Rights Offering Appoints Christopher Shackelton to BioScrip ELMSFORD, N.Y., March 09, 2015 - BioScrip,
Read more →-OPCH
Mar 2, 2015Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com FOR IMMEDIATE RELEASE BIOSCRIP REPORTS FOURTH QUARTER 2014 FINANCIAL RESULTS Elmsford, NY
Communications, Inc. E: lwilson@insitecony.com REPORTS FOURTH QUARTER 2014 FINANCIAL RESULTS Elmsford, NY - March 2, 2015 - BioScrip , Inc. (NASDAQ: BIOS) (the "Company") today announced 2014 fourth quarter financial results. Fourth quarter revenue from continuing operations
Read more →-OPCH
Feb 9, 2015Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Sharon Stern / Nick Lamplough Joele Frank, Wilkinson Brimmer Katcher T: 212-355-4449 FOR IMMEDIATE RELEASE BioScr
In-Site Communications, Inc. E: lwilson@insitecony.com Sharon Stern / Nick Lamplough Joele Frank, Wilkinson Brimmer BioScrip Nominates Three New Independent Announces Agreement with Cloud Gate Capital ELMSFORD, N.Y., February 9, 2015 - BioScrip, Inc. (NASDAQ: BIOS) (the "C
Read more →-OPCH
Feb 4, 2015Lisa Wilson In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com BioScrip Announces Resignation of Hai V. Tran as Chief Financial Officer Company Initiates Search Process for Perm
In-Site Communications, Inc. E: lwilson@insitecony.com BioScrip Announces Resignation of Hai V. Tran as Chief Financial Officer Company Initiates Search Process for ELMSFORD, N.Y., February 4, 2015 - BioScrip, Inc. (NASDAQ: BIOS) (the "Company") today announced that Hai V.
Read more →-OPCH
Nov 5, 2014Hai Tran, Chief Financial Officer BioScrip 952-979-3768 FOR IMMEDIATE RELEASE BIOSCRIP REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS Double Digit Organic Infusion Revenue Growth; Breakeven Cash Flow
Hai Tran, Chief Financial BIOSCRIP REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS Double Digit Organic Infusion Revenue Growth; Breakeven Cash Flow from Continuing Operations Elmsford, NY - November 5, 2014 - BioScrip , Inc. (NASDAQ: BIOS) (the "Company") today announced its
Read more →-OPCH
Aug 6, 2014Hai Tran, Chief Financial Officer BioScrip 952-979-3768 BIOSCRIP REPORTS SECOND QUARTER 2014
Hai Tran, Chief Financial BIOSCRIP REPORTS SECOND QUARTER 2014 FINANCIAL RESULTS N.Y., August 6, 2014 - BioScrip, Inc. (NASDAQ: BIOS) today announced its financial results for the second quarter of 2014. Second quarter revenue from continuing operations was $247.1 million, an
Read more →-OPCH
Jul 18, 2014Hai Tran, Chief Financial Officer BioScrip 952-979-3768
Hai Tran, Chief Financial BIOSCRIP APPOINTS THOMAS PETTIT AS SENIOR VICE PRESIDENT AND CHIEF OPERATING OFFICER ELMSFORD, N.Y., July 18, 2014 - BioScrip, Inc. (NASDAQ: BIOS) (the "Company") today announced that Thomas F. Pettit has been appointed as Senior Vice President and
Read more →-OPCH
May 14, 2014Hai Tran, Chief Financial Officer BioScrip 952-979-3768 BIOSCRIP STOCKHOLDERS ELECT New Independent Director Yon Y. Jorden to board of directors ELMSFORD, N.Y.
Hai Tran, Chief Financial BIOSCRIP STOCKHOLDERS ELECT New Independent Director Y. Jorden to board of directors ELMSFORD, N.Y., May 14, 2014 - BioScrip, Inc. (NASDAQ: BIOS) today announced that at BioScrip's 2014 Annual Meeting held on May 8, 2014, its stockholders voted to e
Read more →-OPCH
May 8, 2014Hai Tran, Chief Financial Officer BioScrip 952-979-3768 or Lisa Wilson In-Site Communications, Inc. 212-759-3929 BIOSCRIP REPORTS FIRST QUARTER 2014
Tran, Chief Financial Officer Communications, Inc. REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS ELMSFORD, N.Y., May 8, 2014 - BioScrip, Inc. (NASDAQ: BIOS) today announced 2014 first quarter financial results. First quarter revenue from continuing operations was $239.6 milli
Read more →-OPCH
Apr 1, 2014BioScrip Completes Sale of Home Health Services Business to LHC Group Elmsford, NY
BioScrip Completes Sale of Home Health Services Business to LHC Group Elmsford, NY - April 1, 2014 - BioScrip , Inc. (NASDAQ: BIOS) today announced that it has completed the previously announced sale of substantially all of its Home Health business, known as Deaconess HomeCar
Read more →-OPCH
Feb 26, 2014Hai Tran, Chief Financial Officer BioScrip 952-979-3768 BIOSCRIP REPORTS FOURTH QUARTER 2013
Hai Tran, Chief Financial BIOSCRIP REPORTS FOURTH QUARTER 2013 FINANCIAL RESULTS ELMSFORD, N.Y., February 26, 2014 - BioScrip, Inc. (NASDAQ: BIOS) today announced 2013 fourth quarter financial results. Fourth quarter revenue from continuing operations was $243.5 million and
Read more →-OPCH
Feb 11, 2014Announces Pricing of 8.875% Senior Notes due 2021
Announces Pricing of 8.875% Senior Notes due 2021 Elmsford, NY - February 6, 2014 - BioScrip , Inc. (NASDAQ: BIOS) ("BioScrip") today announced that it has priced its private placement of $200.0 million aggregate principal amount of 8.875% senior unsecured notes due 2021. The
Read more →-OPCH
Feb 3, 2014TO CREDIT AGREEMENT (this "Amendment") is made and entered into as of December 23, 2013, by and among BIOSCRIP,
THIS FIRST AMENDMENT TO CREDIT AGREEMENT (this "Amendment") is made and entered into as of December 23, 2013, by and among BIOSCRIP, INC., a Delaware corporation (the "Borrower"), each of the Subsidiaries of the Borrower identified on the signature pages hereto as a "Guarantor
Read more →-OPCH
Nov 6, 2013BioScrip reports THIRD QUARTER 2013 financial results Elmsford, NY
reports THIRD QUARTER 2013 financial results Elmsford, NY - November 6, 2013 - BioScrip , Inc. (NASDAQ: BIOS) today announced 2013 third quarter financial results. Third quarter revenue from continuing operations was $208.9 million and the net loss from continuing operations w
Read more →-OPCH
Sep 23, 2013FINAL REMINDER FOR BIOSCRIP 2013 INVESTOR DAY RSVP REQUESTED TO ATTEND Elmsford, NY
FINAL REMINDER FOR BIOSCRIP 2013 INVESTOR RSVP REQUESTED TO ATTEND Elmsford, NY - September 23, 2013 - BioScrip , Inc. (NASDAQ: BIOS) today issued a final reminder regarding its previously announced inaugural Investor Day to be held Tuesday, September 24, 2013, at Le Parker M
Read more →-OPCH
Aug 26, 2013BioScrip COMPLETES ACQUISITION OF carepoint home infusion business Elmsford, NY
COMPLETES ACQUISITION OF carepoint home infusion business Elmsford, NY - August 26, 2013 - BioScrip , Inc. (NASDAQ: BIOS) today announced that it has completed the previously announced acquisition of the business of CarePoint Partners Holdings LLC and its subsidiaries (collec
Read more →Competitive Position
How OPCH ranks across every disease it competes inCompetitive Position is a premium feature
See how OPCH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial